Di-substituted phenethylcarbamic acid esters
Klundt et al.  
 Dl-SUBSTITUTED PHENETHYLCARBAMIC ACID ESTERS Inventors: Irwin L; Klundt, Brookfield; Robert Lenga, Milwaukee, both of Wis.  
 Assignee: Aldrich Chemical Company, Inc.,  
 Milwaukee, Wis.  
 Filed: Dec. 9, 1970 Appl. No.: 96.587  
 [ Apr. 8, 1975 [56] References Cited UNITED STATES PATENTS 3.646.109 2/1972 Shavel. Jr. et al. 260/471 C Primary Eranziner-Lorraine A. Weinberger Assistant Examiner-L. A. Thaxton Almrnc&#39;), Agent. or Firm-Robert L. Niblack; Joyce R. Krei; Vincent A. Mallare [57] ABSTRACT Novel di-substituted a-alkyl-B-phenethylamines and carbamic acid esters. The compounds are antidepressants and anti-hypertensive agents.  
 7 Claims, No Drawings 1 Dl SUBSTlTUTED PHENETHYLCARBAMIC ACID 1 ESTERS a &#34;This invention relates to novel di-substituted a-alkyl- B-phenethylamines and carbamic acid esters represented by the formula 1 whereinz t 1 q R, and-R are.the same or different members of the group consisting of hydrogen, lower alkoxycarbonyl,  
  lower alkox-ycarbamoyl, benzyl, substituted -.benz ylor lower alkanoyl; R is lower alkyl; and R is. hydrogen or wherein R is lower alkyl, lower alkenyl, loweralkynyl, lowerhal oialkyl, cyclopropylmethyl, B-(2.-furyl)e thyl.or azetidinyl, andwhen R, is hydrogen, the pharmaceuti cally acce ptableacid addition salts thereof, with the limitation that when R and R are hydrogen, R, cannot be hydrogen. 7  
  Lower alkenyl refers to both straight and branched chain alkenyl groups containing from 2 to 5 carbon atoms, such as vinyl, allyl, methallyl, l-penteny l, and the like.  
  The term loweralkyl as used herein refers to both straight and branched chain C, C,-, alkyl groups including methyl} ethyl, n-propyl, &#34;iso-p ropyl, n-butyl, sec-butyl, tert-butyl. iso-butyl, n-pen-tyl, iso-pentyl, neo-pentyl, and the like. i  
  Lower alkynyl&#34; refers to C -C,-, alkyl groups as defined aboye from which two hydrogen atoms have been removed from each of two adjacent carbon atoms to produce acetylenicunsaturatio n; e.g., ethynyl, propargyl, Z-butynyl, l-pentynyl, and the like.  
  The term lower alkoxy&#34; refers to alkoxy groups having from 1 to 5 carbon atonis, e.g., methoxy, ethoxy, propoxy, butyroxy, etc.  
  Substituted benzyl&#34; refers to a mono-, di-, or tri-substituted benzyl moiety substituted in the ortho, meta or para positions by a chloro, fluoro, iodo, bromo, or trifluoromethyl atom.  
  Lower alkanoyl refers to alkanoyl groups having from 1 to 5 carbon atoms such as acetate, propionate, butyrate, and valerate.  
 Halo&#34; includes chloro, fluoro, bromo, and iodo.  
  Pharmaceutically acceptable acid addition salts refers to non-toxic acid addition salts which are generally prepared by reacting the amines of this invention with a suitable organic or inorganic acid. Representative salts include the hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, laurate, borate, benz&#39;oate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, and the like.  
  The compounds of this invention exhibit antidepressant activity in mice in the modified dopa test (Everett et al., Fed. Proc., 23, p. 198 (1964). The compounds are useful as antidepressant agents when administered to mammalian patients in dosages offrom 25 to 200 mg/kg of body weight daily. I  
  Compounds wherein R, and R are hydrogen, benzyl, or substituted benzyl are additionally useful as intermediates in the synthesis of compounds wherein R and R are alkoxycarbonyl or alkoxyc&#39;a&#39;rbamoyl.  
  in addition to the antidepressant activity, the compound where R,, R and R are ethoxycarbonyl and R is methyl exhibits antihypertensive activity in rats and dogs and increases renal blood flow in dogs in dosages of from to 200 mg/kgtofgbodyweight daily. Thev compound is thus additionally&#39;useful in the treatment of renal hypertension and shock.  
  The compounds are preferably administered to mammalian&#39;patients in dosagesof from 25 to 200 mg/kg of body weightdaily, preferably in divided dosages. While the compounds exhibit both oral and parenteral activ ity, the preferred route-.of administration in the treatment of depressionandhype-rtension is the oral route. For treating shock, the parenteral route is the preferred route. of administration;  
 Representative compounds of this invention include:  
 3,4-Dibenzyloxy-a-methylrfi phenethylcarbamic acid, ethyl ester 3,4-Dihydroxy-a-methyI B-phenethylcarbamic acid,  
  ethyl ester I 3,4-0,0-bis(ethoxycarbonyl)ia-methyLB-phenethylcarbamic acid, ethyl ester 3-l-lydroxy-4-benzyloxy-oz-methyl-B-phenethylcarbamicacid, ethyl ester 3,4 Dihydr0xyfozf methyl-B-phenethylcarbamic acid,  
 , B-(2 fur yl)ethyl ester ,3,4 Dibenayloxy-a-ethyl-B-phenethylamine 3,4-,0,0;bi s(methoxycarbonyl oz-methyl-B-phenethylcarbamic acid, propargyl ester 3 l-Dihydroxy-o -n-propyl-B-phenethylamine ,The compounds of this invention are prepared by wel l known procedures. Generally speaking, protocatec hualdehyde.( Aldrich Chemical Co.) is reacted with R Cl (i. e., benzyl chloride). The resulting compound is converted to the corresponding B-methylnitrostyrene, by methods well known in the art, which is then treated with lithium aluminum hydride. The resulting amine is then converted to the corresponding .isocyanate and then reacted withanappropriate alcohol. Removal of the catechol protecting group and treatment with an appropriate chloroformate or isocyanate yields the desired products.  
  The followingexamples further illustrate the present invention. .-i 1  
  Pr eparationof I 3.,4-Dibenzyloxyfl-Methyl-B-Phenethylcarbamic Acid, Ethyl Ester 3 Analysis Calcd. for C ,;H NO C,74.46; H,6.82;  
  N,3.34 Found: C,74.l4; H,7.l l; N,3.36  
 EXAMPLE 2 Preparation of 3,4-Dihydroxy-a-Methyl-B-Phenethylcarbamic Acid, Ethyl Ester To 300 ml of methanol was added l4.4&#39;g of 3,4- dibenzyloxy-a-methyl-B-phenethylcarbamic acid. ethyl ester (prepared according to the method of Example 1 and 500 mg of palladium on charcoal as a waterwetted paste. The reaction was hydrogenated at atmospheric pressure. The catalyst was filtered off and the solvent removed in vacuo leaving a syrup. The syrup was chromatographed through 900 g silica gel using ethyl acetate as the elutant. The first 600 ml contained no product. The next 800 ml contained 6.4 g (78%) of the product as a syrup which was dried under high vacuum overnight.  
 Analysis Calcd. for C H NO C,60.25; H,7.ll;  
  N586 Found: C.60.l9; H.694; N,5.54  
 EXAMPLE 3 Preparation of 3,4-Dicarbethoxy-a-MethyhB-Phenethylcarbamic Acid, Ethyl Ester To 100 ml chloroform was added 5.2 g (0.02l8 mole) of 3,4-dihydroxy-a-methyl-B-phenethylcarbamic acid, ethyl ester (prepared according to the method of Example 2), followed by 4.8 g (0.0436 mole) of ethyl chloroformate. To the reaction was added dropwise 4.4 g (0.0436 mole) of triethylamine in ml of chloroform. The reaction was refluxed overnight. The solution was washed with water (2X200 ml) and dried. Evaporation of the chloroform in vacuo gave a yellow syrup which solidified upon standing. The solid was dissolved in 350 ml of hot cyclohexane containing 20 ml of benzene to yield 6.9 g of product as a white solid, mp. ll31l5.  
 Analysis Calcd. for C M- N0 C.56.38; H.653;  
 Found: C.56.52; H.655; N,3.72  
  The compounds useful in the practice of the present invention are generally formulated into pharmaceutical compositions comprising, as an active ingredient, at least one of the active agents in association with a pharmaceutical carrier or diluent. The compounds useful in the practice of the invention exhibit both oral and parenteral activity and can be formulated in dosageforms for oral, or parenteral administration.  
  Solid dosage forms for oral administration include capsules, tablets, pills. powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate, sweetening and flavoring agents, and the like. In the case of capsules, for example, the active agent may be the sole ingredient.  
 Liquid dosage forms for oral administration include,  
 pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Besides inert diluents, such compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.  
  Preparation according to this invention for parenteral administration include sterile aqueous or nonaqueous solutions, suspensions or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol. polyethylene glycol, vegetable oils, such as olive oil and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as pre serving, wetting, emulsifying and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.  
  The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient shall be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment.  
 We claim:  
 1. A compound of the formula l R10 CHz-CH-NHRz,  
 wherein R and R each are lower alkoxy carbonyl or benzyl, R is lower alkyl and R, is  
 R being lower alkyl, lower alkenyl, lower alkynyl, cy-